JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research

December 13, 2007

Copenhagen, Denmark - December 13, 2007 - The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, awarded Professor Jens Høiriis Nielsen, from the University of Copenhagen's Department of Medical Biochemistry and Genetics, a research grant for $495,000 to study beta cell regeneration and expansion during pregnancy with the objective of discovering new approaches for the treatment of type 1 diabetes.

The project, "Beta Cell Expansion: Lessons from Pregnancy," is aimed at studying the mechanisms responsible for the increase in insulin-producing beta cells during pregnancy. Experiments with mice have shown that increased levels of pregnancy hormones are involved in the proliferation of beta cells. Dr. Nielsen will now study the effect of serum from pregnant women on human beta cell proliferation and survival in isolated islets. The successful identification of the factors in pregnant human serum and understanding the signaling pathways involved in the expansion of insulin producing beta cells may ultimately lead to new regenerative drugs and therapies for type 1 diabetes.

"This award will allow us to devote our research effort to unravel the mechanisms behind the beta cell expansion in pregnancy. We will work together with experts in protein chemistry from Novo Nordisk and in bioinformatics from the Institute for Systems Biology in Seattle, as well as other scientists engaged in the JDRF funded program," said Dr. Nielsen. "By identification of growth factors and signaling pathways that promote expansion of the functional beta cell mass, new drug targets may be discovered that may lead to new ways of treatment of type 1 diabetes."

"The University of Copenhagen's novel work on beta cell regeneration and the effect pregnancy hormones have on human islet cell production, are key steps in understanding regeneration," said Patricia Kilian, Ph.D., Therapeutic Program Director for Regeneration research at JDRF. "This initiative meets a critical JDRF research goal and more importantly has the potential to create applicable cure therapeutics for type 1 diabetes patients."
-end-
Additional details about the proposed study and other research funded by JDRF may be seen by visiting JDRF's website (www.jdrf.org) and clicking on the link labeled "Abstracts of JDRF-funded research."

About JDRF Denmark

JDRF Denmark is the latest affiliate addition to the globally growing JDRF family.

Established in 2003, the affiliate was run on volunteer basis for the first 4 years. In February 2007 the affiliate was staffed by two key persons from the founding board, Finn Kristensen and Lisbeth Wigéll. Fundraising activities include walks, the international Death Valley Ride to Cure Diabetes, Cruise for a Cure, golf tournaments, soccer collection events, holiday greeting cards, private donations, memberships and partnerships with the business community. For more information please visit www.jdrf.dk.

About JDRF

JDRF was founded in 1970 by the parents of children with type 1 diabetes - a disease that strikes children, adolescents, and adults suddenly, makes them insulin dependent for life, and carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.16 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. For more information please visit www.jdrf.org.

JDRF

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.